EBOV VLP

EBOV VLP Full Name

Zaire Ebola Virus Virus Virus-like Particles

EBOV VLP Introduction

Ebola virus-like particles (VLPs) are non-infectious, self-assembling nanostructures that closely mimic the morphology and surface antigenic composition of native Ebola virions but lack the viral genome and therefore cannot replicate or cause disease. EBOV VLPs are typically produced by co-expressing the major structural proteins of Ebola virus—most commonly VP40 (the matrix protein), GP (the envelope glycoprotein), and NP (the nucleoprotein)—in mammalian or insect cell expression systems. When VP40 is expressed alone, it is sufficient to drive the budding of filamentous, virus-like particles from the cell membrane, recapitulating the characteristic filamentous shape of Ebola virions. The incorporation of GP into VLPs provides the critical surface spike structures that are the primary targets of neutralizing antibody responses, while NP incorporation enhances the particulate nature and immunogenic payload of the VLPs. The resulting particles are typically filamentous, approximately 80 nm in diameter and up to several micrometers in length, and display GP trimers on their surface in a native-like conformation. EBOV VLPs have been extensively characterized using electron microscopy, dynamic light scattering, and immunoassays to confirm their structural fidelity and antigenic authenticity. Because they contain no genetic material, EBOV VLPs offer an inherently safe vaccine platform that can be handled without the stringent biosafety level 4 (BSL-4) containment required for live Ebola virus work, making them highly attractive for both research applications and clinical vaccine development.

Figure 1. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.

The immunological mechanism by which EBOV VLPs elicit protective immune responses involves multiple arms of the innate and adaptive immune system. Upon administration, VLPs are efficiently taken up by antigen-presenting cells, particularly dendritic cells and macrophages, through a combination of phagocytosis and receptor-mediated endocytosis. The particulate nature of VLPs—typically in the 50-200 nm range—closely matches the optimal size for lymph node trafficking and B cell receptor cross-linking, resulting in strong humoral immune activation. GP displayed on VLP surfaces is presented to B cells in its native trimeric conformation, eliciting conformation-dependent neutralizing antibodies that recognize key epitopes including the receptor-binding domain, the glycan cap, and the mucin-like domain. VLPs also efficiently stimulate CD4+ T helper cells through MHC class II antigen presentation and can activate CD8+ cytotoxic T lymphocytes via cross-presentation through MHC class I pathways, which is critical for eliminating virus-infected cells. The intrinsic adjuvant properties of VLPs are partly attributed to their ability to activate innate immune sensors, including Toll-like receptors and the NLRP3 inflammasome, leading to the production of pro-inflammatory cytokines and type I interferon. Studies in animal models have demonstrated that EBOV VLPs immunization generates robust GP-specific IgG titers, neutralizing antibody responses, and T cell memory that persist for extended periods. The inclusion of NP in VLP formulations further broadens the T cell repertoire, as NP-derived epitopes are presented alongside GP epitopes, providing a multi-antigenic stimulus that may enhance protection against viral escape variants.

EBOV VLPs hold significant clinical promise as a next-generation vaccine platform for Ebola virus disease, offering several advantages over traditional vaccine approaches. Unlike live-attenuated or replication-competent vaccines, VLPs are non-replicating and non-infectious, eliminating safety concerns associated with reversion to virulence or unintended spread in immunocompromised populations. Preclinical studies in mice, guinea pigs, and nonhuman primates have consistently demonstrated that EBOV VLPs can confer complete protection against lethal EBOV challenge, with immunization schedules as short as two doses administered three weeks apart. The VLP platform is also amenable to rapid modification to incorporate GP variants from different Ebola virus species or strains, enabling the development of multivalent or pan-filovirus vaccines. From a manufacturing perspective, VLPs can be produced at scale using established bioprocessing technologies, including baculovirus-insect cell and mammalian cell expression systems, with purification protocols based on ultracentrifugation and chromatographic methods. Clinical development of EBOV VLPs has progressed through early-phase trials, with safety and immunogenicity data supporting further advancement. Combination strategies incorporating VLPs with adjuvants such as alum, MPLA, or TLR agonists have shown enhanced immunogenicity, potentially allowing dose-sparing and improved responses in vulnerable populations. Looking forward, the EBOV VLP technology may be adapted for use as a heterologous prime-boost strategy alongside viral vector or mRNA-based Ebola vaccines, leveraging complementary immune mechanisms to achieve broader and more durable protection. The platform also has potential applications beyond vaccination, including as a diagnostic reagent and as a tool for serological surveillance in outbreak settings.

Alternate Names for EBOV VLP

EOBV; Zaire ebolavirus; Zaire Ebola Virus Virus-like Particles; Ebola Virus; VLP; ebolavirus; EBOV VLP

• 1. Warfield KL et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2015;211(Suppl 2):S322-S329.
  2. Licata JM et al. Ebola virus-like particles: preparation and characterization. Methods Mol Biol. 2018;1628:157-172.
  3. Kessell AJ et al. Immunogenicity and protective efficacy of Ebola virus-like particles administered In Vivo with matrix-M adjuvant. Vaccine. 2021;39(24):3353-3362.
  4. Wong G et al. Immunization with vesicular stomatitis virus-vectored Ebola vaccines alone or in combination with virus-like particles confers complete protection. J Infect Dis. 2018;218(Suppl 5):S348-S355.
  5. Wu et al. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses. Viruses. 2020. doi: 10.3390/v12010064